A study of incidence and characteristics of infections in 476 patients from a single center undergoing autologous blood stem cell transplantation.

Int J Hematol 2007 Aug;86(2):186-92

Hematology Service, University Hospital La Fe, Valencia, Spain.

Infectious complications are a major cause of morbidity and mortality in patients who undergo autologous stem cell transplantation (ASCT). We examined 476 patients with hematologic malignancies (401) or solid tumors (75) who underwent ASCT between February 1990 and May 2005. Anti-infectious prophylaxis consisted of different combinations of ciprofloxacin, cotrimoxazole, fluconazole, aerosolized amphotericin B, acyclovir, and intravenous immunoglobulins. Overall, 454 patients (95%) developed fever in the first 60 days after ASCT. In the majority of patients, initial antibiotic therapy consisted of broad-spectrum beta-lactamic with or without amikacin. A glycopeptide was administered as initial therapy in 86 cases. Overall, there were 132 (29%) clinically documented infections (37 pneumonias), 79 (17%) microbiologically documented infections (65 bacteremias), and 243 (54%) fevers of unknown origin. Coagulase-negative staphylococci (18, 25%) and E coli (18, 25%) were the organisms most frequently isolated. The pattern of infection did not change throughout the study except for a significantly higher incidence of bacteremia due to gram-positive bacteria in the first 5 years of the study. Infection-related mortality was 5% (21 cases), with pneumonia the most frequent cause of death. ASCT should be considered a low-risk procedure, although new therapeutic approaches for patients developing severe respiratory infections are still needed.

Download full-text PDF

Source
http://link.springer.com/10.1532/IJH97.E0633
Publisher Site
http://dx.doi.org/10.1532/IJH97.E0633DOI Listing
August 2007
3 Reads

Publication Analysis

Top Keywords

476 patients
8
documented infections
8
cell transplantation
8
stem cell
8
patients
6
29% clinically
4
clinically documented
4
therapy cases
4
administered initial
4
initial therapy
4
cases 132
4
132 29%
4
pneumonias 17%
4
243 54%
4
54% fevers
4
fevers unknown
4
bacteremias 243
4
infections bacteremias
4
glycopeptide administered
4
17% microbiologically
4

References

(Supplied by CrossRef)

Similar Publications